Skip to content

Ionis Pharmaceuticals

US · IONS #1749 by market cap Listed 1970
26.58 -0.64 -2.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 34 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.2 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
114.70% +4.22pp
Institutions
595 -34
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund90.80%
Hedge Fund12.49%
Public Company6.14%
VC/PE Fund1.79%
Private Company1.69%
Government Pension Fund1.30%
Individual/Insider0.78%
Insurance Company0.29%

Top holders as of 2026-09-30

FMR 14.85% · 24.74M sh
Capital Research 13.28% · 22.12M sh
BlackRock 7.92% · 13.19M sh
Vanguard Portfolio Management, LLC 4.64% · 7.72M sh
Wellington Management Group 4.59% · 7.65M sh
Vanguard Capital Management, LLC 4.33% · 7.22M sh
T. Rowe Price Group, Inc. 4.29% · 7.14M sh
Two Sigma Investments, LP 3.75% · 6.25M sh
State Street Global Advisors 3.43% · 5.71M sh
Geode Capital Management, LLC 1.97% · 3.28M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 29 buys · 21 sells

NameRoleStake
Brett Monia Chief Executive Officer 0.15%
Spencer Berthelsen Independent Director 0.10%
Brian Birchler Executive Vice President of Corporate & Development Operations 0.06%
Elizabeth Hougen Chief Financial Officer 0.05%
Michael Hayden Independent Director 0.05%
Eugene Schneider Executive VP, Chief Clinical Development & Operations Officer 0.05%
C. Bennett Chief Scientific Officer 0.05%
Richard Geary Strategic Consultant 0.04%
Patrick O'Neil Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary 0.04%
Joseph Baroldi Executive VP & Chief Business Officer 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Michael Hayden Independent Director Open Market Acquisition +5,000 $29.64
2026-10-15 Eric Swayze Executive Vice President & Head of Research Derivative Exercise and Sale -53 $43.54
2026-10-15 Shannon L. Devers Executive VP & Chief Human Resource Officer Derivative Exercise and Sale -1,357 $43.54
2026-10-15 Shannon L. Devers Executive VP & Chief Human Resource Officer Intent to Sell (Form 144) -1,357 $44.00
2026-10-14 Eric Swayze Executive Vice President & Head of Research Derivative Exercise and Retained +72 --
2026-10-14 Shannon L. Devers Executive VP & Chief Human Resource Officer Derivative Exercise and Retained +1,463 --
2026-08-30 C. Bennett Chief Scientific Officer Other Acquisition +110 $51.31
2026-08-30 Brett Monia Chief Executive Officer Other Acquisition +98 $51.31
2026-08-30 Patrick O'Neil Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Other Acquisition +63 $51.31
2026-08-30 Brian Birchler Executive Vice President of Corporate & Development Operations Other Acquisition +58 $51.31
2026-07-30 Michael Hayden Independent Director Open Market Acquisition +20,000 $51.60–53.38
2026-07-14 Joan Herman Independent Director Derivative Exercise and Retained +5,220 --
2026-07-14 Spencer Berthelsen Independent Director Derivative Exercise and Retained +5,220 --
2026-07-14 Ludwig Hantson Director Other Derivative Acquisition +3,399 --
2026-07-14 Peter Reikes Director Other Derivative Acquisition +3,399 --
2026-07-06 C. Bennett Chief Scientific Officer Other Acquisition +15,000 --
2026-07-06 C. Bennett Chief Scientific Officer Automatic Disposition -20,536 $83.58–85.46
2026-07-06 C. Bennett Chief Scientific Officer Other Derivative Disposition -15,000 --
2026-07-06 Allene Diaz Independent Director Derivative Exercise and Sale -10,111 $47.11–85.42
2026-07-06 Holly Kordasiewicz Chief Development Officer Automatic Disposition -362 $84.30

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:59:29 · For reference only, not investment advice and not tailored to your situation.

Ionis Pharmaceuticals discussion 0 comments

Add a comment